ETX-155
| Clinical data | |
|---|---|
| Other names | ETX155 |
| Routes of administration | Oral[1][2] |
| Drug class | GABAA receptor positive allosteric modulator; Neurosteroid |
| Pharmacokinetic data | |
| Elimination half-life | 24–40 hours[3][4] |
ETX-155 is a GABAA receptor positive allosteric modulator and neurosteroid which is or was under development for the treatment of depressive disorders, seizures, and fibromyalgia.[1][5][2][3][4] It is taken orally and has an elimination half-life of 24 to 40 hours.[1][2][3][4] The drug produces antidepressant-like, anxiolytic-like, and anticonvulsant effects in rodents.[3][4] Side effects of ETX-155 in humans include somnolence, fatigue, dizziness, and headache.[3][4] ETX-155 was originated by Athenen Therapeutics and is or was under development by Climb Bio and/or Eliem Therapeutics.[1][5][2] As of October 2024, development of the drug for all indications has been suspended or discontinued.[1][5][2] It reached phase 1 clinical trials prior to the suspension or discontinuation of its development.[1][5][2]
See also
References
- ^ a b c d e f "ETX 155". AdisInsight. 8 October 2024. Retrieved 18 May 2026.
- ^ a b c d e f "ETX-155 Drug Profile". Ozmosi. 1 January 1900. Retrieved 18 May 2026.
- ^ a b c d e Perucca E, White HS, Bialer M (September 2023). "New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development". CNS Drugs. 37 (9): 781–795. doi:10.1007/s40263-023-01025-4. PMC 10501930. PMID 37603261.
- ^ a b c d e Versavel M (June 2022). "ETX-155, A novel GABAA positive allosteric modulator". Presentation given at the 2022 Epilepsy Foundation Pipeline Conference. Santa Clara, CA: Eliem Therapeutics, Inc.
- ^ a b c d "Delving into the Latest Updates on ETX-155 with Synapse". Synapse. 9 May 2026. Retrieved 18 May 2026.